NovaSure Model 10 RF Controller
Hologic, Inc. · Decision date Dec 17, 2025
What did the FDA decide?
FDA records P010013/S094 as a supplement to PMA P010013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 17, 2025.
FDA approval order statement
a new supplier of the LCD screen
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Dec 17, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P010013/S094
- Regulatory pathway
- PMA supplement
- Applicant
- Hologic, Inc.
- Product code
- MNB
- Decision code
- OK30
- Decision date
- Dec 17, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, thermal ablation, endometrial.
- Applicant
- Hologic, Inc.
- Product code
- MNB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P010013/S094 received
Application receipt date recorded by FDA.
P010013/S094 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P010013. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MNB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MINERVA ENDOMETRIAL ABLATION SYSTEMP140013/S019 | Axora Medical, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| Channel Medsystems, Inc. | PMA supplement | Nov 3, 2026 | FDA | |
Cerene Cryotherapy DeviceP180032/S024 | Channel Medsystems, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Minitouch 3.8 Era System (Minitouch System)P230002/S002 | MICROCUBE, LLC | PMA supplement | Jul 13, 2026 | FDA |
Cerene Cryotherapy DeviceP180032/S023 | Channel Medsystems, Inc. | PMA supplement | Jul 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Hologic, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 250 Campus Dr., Malborough, MA, 01752
Sources and methodology
- Original FDA record: P010013/S094
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


